One of the most exciting changes that will occur in the next few months is the transition of the journal *Neuro-Oncology* from Duke University Press to Oxford University Press. The growth of the Society and expanding submissions of research completed by the membership has mandated that we move to a monthly publication to ensure timely dissemination of important work. This transition could not have been possible without the support of Duke University Press during the early years of the journal, the generous endorsement from the Pediatric Brain Tumor Foundation, and the vision and initiative of Darell Bigner. The continued success of the journal is in large part due to the dedication of the editor-in-chief, W.K. Alfred Yung, and executive editors C. David James, Michael Weller, and Ryo Nishikawa, who have consistently set high standards for the journal.

Our efforts to increase international relations also continue to expand. The International Fellowship generously supported by the American Brain Tumor Association (ABTA) and EMD Serono, will provide a program for professionals from outside North America to perform clinical, translational, or basic research in the area of pediatric or adult neuro-oncology in a clinical and/or laboratory setting in the United States or Canada.

I would like to especially thank the SNO Foundation directors Edward Shaw, Mitchel Berger, Victor Levin, and Mark Gilbert and the members of the Partners Advisory Council for their continued support and guidance as the Society takes on more initiatives. I would also like to recognize the multidisciplinary members of the Board of Directors for their input into critical aspects of operating the Society. Special thanks go to Chas Haynes, Jan Esenwein and Linda Greer for administrative support – which has been critical for providing the continuity needed to allow smooth transitions between leadership periods – and for always striving to improve the foundation of support for the Society. I look forward to continued participation on the Board of Directors as past president and welcome the incoming leadership.

**Susan M. Chang**
SNO President
Dear Society Members,

It is with great pleasure that I submit the 2009 Annual Report to the membership and friends of our Society. Despite the challenges faced by all of us in this difficult economic climate, the Society for Neuro-Oncology has had an excellent year, and I believe we are well positioned to build upon the various initiatives outlined in this Report. To be sure, we are all indebted to the SNO Board of Directors, the SNO Foundation and our member volunteers for their able guidance and support during these uncertain times.

Members of the Society can look forward to significant changes to our flagship publication, Neuro-Oncology. After a thorough RFP process, it was determined that Oxford University Press (OUP) was the publisher best suited to take the journal to the next level in terms of international distribution and editorial excellence. As the world’s largest and oldest university press, OUP is known for its breadth and high quality, while at the same time offering unparalleled support to its society partners, editors and authors. The most obvious change will be a move to a monthly publication schedule which will effectively double the number of articles printed in Neuro-Oncology each volume year. The lead-time to publish articles on-line will be dramatically reduced, as will the time it currently takes for articles to appear in the printed pages of the journal. Other changes, although perhaps less apparent but nevertheless important, will involve leveraging OUP’s significant global presence to increase international subscriptions, maximize penetration into the institutional market and improve consortia sales. Under the editorial care and guidance of editor-in-chief W. K. Alfred Yung, we are indeed entering an exciting new phase of the journal’s evolution, and I believe we are well positioned to build upon the various initiatives outlined in this Report and will also be seeking new corporate and individual funding opportunities for our Society and help to improve the care and treatment of patients with brain tumors.

The SNO administrative office and communications committee co-chair Erik Sulman have been working to launch the new SNO website, which by the time this Annual Report is disseminated will be up and running. Far from merely a visual redesign, our new internet presence will represent a fundamental change in the way SNO members interact with the administrative office. Overall, these changes will not only improve the content available on our site, but also provide for a more seamless, convenient user experience.

I am pleased to report that our 13th Annual Scientific Meeting and Education Day, held in Las Vegas in November of 2008, was the most successful event in our history. With Michael Vogelbaum organizing the scientific program, Patrick Wen heading up the Education Day, and Sherry Fox organizing the Quality of Life sessions, the meeting received over 550 abstract submissions representing a new record for a SNO meeting. We also enjoyed a positive gain in attendance with over 1200 international and US-based registrants overall. Along with our sister neuro-oncology societies, SNO was also pleased to participate in the World Federation of Neuro-Oncology (WFNO) meeting that was held in May, 2009, in Yokohama, Japan, which was an overwhelming success both in terms of scientific content and international participation. Last but not least on the meeting front, under the guidance of Frederick Lang and Randy Jensen, SNO anticipates an excellent collaborative meeting with the AANS/CNS Section on Tumors in New Orleans this fall.

Our International Outreach efforts continue to evolve, and with generous support from the American Brain Tumor Association and EMD Serono, SNO launched a new International Outreach Research Fellowship which will allow for a professional from outside North America to perform clinical, translational or basic research in the area of pediatric or adult neuro-oncology in a clinical and/or laboratory setting in the United States or Canada. We are delighted to have secured the funding for this fellowship award through 2012.

The Society is deeply grateful to our president Susan Chang who, despite the challenges presented by the global economic downturn, has calmly guided our Society into new and exciting areas. SNO also thanks our dedicated matriarch Jan Esenwein and administrative manager Linda Greer, whose dedication to our mission remains unbounded. The year ahead holds many opportunities for our Society and we have generated a great deal of momentum as we move forward. We will continue to develop the initiatives outlined in this Report and will also be seeking new ways that the SNO administrative office can help in the planning and organization of joint meetings and collaborative projects. As always, we welcome your suggestions and ideas so that SNO may better serve the neuro-oncology community and help to improve the care and treatment of patients with brain tumors.

J. Charles Haynes, JD
SNO Executive Director

Dear Society for Neuro-Oncology Members and Supporters,

Despite the economic challenges faced by all non-profit organizations, the Society for Neuro-Oncology continues to grow and mature. SNO is proud to provide a variety of educational resources to better assist the clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.

In order to fund the initiatives outlined in the pages of this Report, the Society relies in large part on the support of our foundation and corporate partners, as well as the generosity of our members. SNO has four programs—the Annual Meeting Sponsorship Program, the Partner’s Advisory Council, the President’s Club, and the Victor Levin Founder’s Society—which sustain our vision and mission. The Annual Meeting Sponsorship Program has facilitated growth in the Society’s premier education event. Those non-profit associations, foundations and societies, and corporate donors who support the annual meeting at the highest level with a multi-year commitment are members of the Partner’s Advisory Council, which has direct access to the SNO Board of Directors and Foundation Board on a regular basis. Current members of the Council include the American Brain Tumor Association, EMD Serono, Genentech, the National Brain Tumor Society, the Pediatric Brain Tumor Foundation, Schering-Plough Oncology and the Sontag Foundation. The President’s Club provides annual giving opportunities for individual members of the Society. Through endowment, future Society-supported educational and research endeavors of the Society will be funded by the Victor Levin Founder’s Society.

Now more than ever we would ask you to consider how you may contribute to the Society with your time or financial resources. Together we can help achieve the goal we all share—to find a cure for brain tumors!

Sincerely,

Mitchel S. Berger, MD, Mark R. Gilbert, MD, Victor A. Levin, MD and Edward G. Shaw, MD (Foundation President)
The 2008 SNO Meeting and Education Day was held at the Loews Resort in Lake Las Vegas, Nevada.

The 2008 Society for Neuro-Oncology Scientific Meeting held at the Loews Las Vegas Resort in Lake Las Vegas, Nevada, on November 21–23, 2008 was a huge success. The meeting, which drew a record number of abstracts (565, up 15% from 2007) and attendees (over 1200, an increase of over 33% from 2007!) began as usual with an Education Day on Thursday.

The 2008 SNO Education Day, chaired by Patrick Wen, included a balance of updates on translational research, basic science and clinical care. It was held in parallel with a Quality of Life program chaired by Sherry Fox. The Education Day program attracted a large audience of over 500 registrants; a new record for SNO.

The morning session focused on the limitations of current therapies for brain tumors and Strategies To Overcome Resistance with an overview of the current status of targeted molecular therapies, including inhibitors of angiogenesis, and their limitations. During lunch, Arie Perry gave an update on the changes in the new World Health Organization (WHO) Classification of brain tumors that was introduced in 2007. In the afternoon two concurrent sessions were held, one devoted to the relatively new and important area of RNA interference (RNAi) which is revolutionizing cancer research, and the other devoted to supportive care issues that significantly affect the quality of life for brain tumor patients. The final session of the Education Day program involved debates on two common clinical problems facing neuro-oncologists: the merits of adjuvant chemotherapy in patients with anaplastic oligodendrogliomas and the risks and benefits of radiation therapy versus chemotherapy for low-grade gliomas.

The formal meeting, chaired this year by Michael Vogelbaum, began on Friday with three concurrent and very well-attended Sunrise sessions focusing on the biology of glioma invasion, low grade gliomas, and glioma epidemiology and markers. The Plenary session opened with a session focused on the highest scoring abstracts. Most of the abstracts in this session were also selected for awards, which were presented to the authors at the time of their presentation. The second half of the opening plenary session was focused on advances in imaging of tumors and therapeutic responses. A special luncheon lecture was given by Jiri Bartek on the topic of DNA damage checkpoints. Friday afternoon brought concurrent sessions focusing on the latest results from clinical trials and advances in cell biology. The concurrent sessions were followed by a new presentation format; a poster discussion session. The poster discussion session consisted of a 1-hour period of viewing the highest ranked posters, followed by a 1-hour discussion of the posters by a select panel of senior investigators. The general posters were available for viewing on Friday evening.

Saturday began with three additional concurrent sunrise sessions devoted to ependymomas, epigenetics and a panel discussion of whether more chemotherapy is better. The Saturday morning plenary session focused on stem cell biology and pediatric neuro-oncology basic science. These two topics were featured in separate keynote lectures given by Richard Gilbertson (stem cells) and David Largaespada (pediatric basic science). Saturday afternoon brought concurrent sessions focused on pathology and prognostic markers, and epidemiology and quality of life. The second poster discussion session followed the concurrent sessions, and this in turn was followed by the second general poster session. Saturday evening brought the SNO banquet which featured the presentation of the SNO Lifetime Achievement Award to Charles Wilson, M.D.

Sunday morning brought three additional sunrise sessions on advanced technology in radiation oncology, neurocognition and quality of life, and immunotherapy. The Sunday morning plenary session started with a focus on immunotherapies and then closed with an excellent series of abstracts focused on experimental therapeutic approaches.

The meeting adjourned at noon on Sunday with the hope that all present would be able to attend the 2009 joint meeting of SNO and the AANS/CNS Section on Tumors in New Orleans.
Spotlight on the Journal

Neuro-Oncology

SNO’s official journal, Neuro-Oncology, has continued to increase the amount of information it contributes to the community of scholars, investigators, and clinicians involved in helping SNO meet its goal of advancing multidisciplinary research and education in the field of neuro-oncology. The journal’s contribution to this mission is reflected in the increasing number of papers published and its continued dominance among neuro-oncology journals. Now, the journal is poised to take on an even bolder agenda, doubling its frequency from bimonthly to monthly through its new affiliation with Oxford University Press.

Second Year of Bimonthly Publishing Prompts Further Journal Growth

In 2008, Neuro-Oncology jumped from quarterly to bimonthly publication, running almost 1200 pages of text (including abstracts from 5 major meetings: the 13th International Symposium on Pediatric Neuro-Oncology, the 8th Congress of the European Association for Neuro-Oncology, and the 13th Annual Meeting of the SNO). In 2009, the journal is expected to publish about 1050 pages of text, with abstracts from the 17th International Conference on Brain Tumor Research and Therapy, the World Federation of Neuro-Oncology 2009 Meeting, and the 2009 Joint Meeting of SNO and the AANS/CNS Section on Tumors. These meetings represent the pinnacle events in the neuro-oncology community, and their published abstracts receive high levels of readership throughout the year.

As the journal has continued to accelerate its publication schedule and has maintained its predominance in the field in terms of its impact factor, the number of high-quality research papers submitted has also grown. In 2007, the journal received 285 new and 68 revised manuscripts; in 2008 submissions had increased to 373 new and 129 revised manuscripts (well above the 347 new and 116 revised papers anticipated). At the time this report was being prepared (Aug. 31, 2009), the editorial office had already received 314 new articles and 75 revised articles to consider for publication in 2009; if this pace of submissions continues, the journal’s editors (Editor-in-Chief W. K. Alfred Yung, SNO Executive Editor G. David James, EANO Executive Editor Michael Weller, and JSNO Executive Editor Ryo Nishikawa) will have coordinated reviews and decision making on 469 new submissions and 112 revised manuscripts, about 65% more manuscripts than just 2 years ago.

Impact Factor Keeps Journal at the Top

Neuro-Oncology’s impact factor number now stands at 5.000, down from last year’s 5.806, but still significantly above its nearest direct competitor. Neuro-Oncology remains in the top 25% of both oncology journals (where it is ranked 25th of 141 journals) and clinical neurology titles (where it is 15th of 156 journals). The decline in impact factor was not unexpected because the total number of scientific articles published in 2007 represented a nearly 60% increase from the previous year (46 vs. 29 in 2006). In 2008, 76 scientific articles were published and for the 2009 volume, 71 scientific articles were being published, along with the abstracts named above, various editorials, book reviews, society news and other announcements, and letters to the editor. The upward trend in published articles will continue into the foreseeable future, as the journal moves to monthly publication in 2010. In doing so, the aim is to see not only renewed increases in the impact factor but, more important, growth in Neuro-Oncology’s impact on the neuro-oncology community and service to patients with brain tumors.

The journal is indebted to the tireless members of its editorial board (whose names appear in every issue of the journal) and other peer reviewers (see sidebar), all of whom have helped it reach and maintain our enviable position.

Peer Reviewers: Neuro-Oncology

Alex McMillan
Louis Burt Nahors
Mitutoshi Nakada
Hidehito Okada
Marios Papadopoulos
John Park
Andrew T. Parsa
Vinay K. Puduvalli
Jeffrey J. Raizer
Lisa R. Rogers
Tena Rosser
Robert Rontomily
James Rubenstein
Jann N. Sarkaria
David Schiff
Hiroki Shirato
Riccardo Soffietti
Yukihiko Sonoda
Shingo Takano
Martin J. B. Taphoorn
Christopher D. Turner
Jeffrey S. Wefel
Patrick Y. Wen
Wolfgang Wick
John K. Wientcke
Shiao Y. Woo
Ryuya Yamanaka
Ping Yang
Seitchi Yoshida
Xiang Zhang

A New Publishing Partner

Oxford University Press (OUP) is the world’s largest university press. OUP has had an active journal-publishing program since the start of the last century and is a leader in electronic journal publishing.

OUP is a department of Oxford University. It furthers the university’s objective of excellence in research, scholarship, and education by publishing worldwide. As a department of the university, the press shares the university’s status as a charity—it has no shareholders. Any financial surplus is applied in the pursuit of the educational and scholarly objectives of the university and its press, either through financial returns to society partners, reinvestment in publishing programs, or the transfer of funds to the university.
In recent years, the Society for Neuro-Oncology has made a concerted effort to promote international clinical and research activities in both pediatric and adult neuro-oncology in the developing world. The urgency for these efforts to yield results have never been greater. As Jonathan Finlay, the SNO International Outreach Committee Chair, pointed out during his presentation at the World Federation of Neuro-Oncology meeting in Yokohama, Japan, survival rates for brain cancer in underserved areas can be as much as one-tenth when compared to the United States. Clearly, much needs to be done, but with the assistance of our SNO Partners and member volunteers, we are now able to offer several educational opportunities to our colleagues in areas where neuro-oncology education is needed most.

**SNO International Outreach Research Fellowship**

With generous support from the American Brain Tumor Association (ABTA) and EMD Serono, this year the Society for Neuro-Oncology established a new International Outreach Research Fellowship. The purpose of this one-year fellowship is to provide a program for professionals from outside North America to perform clinical, translational or basic research in the area of pediatric or adult neuro-oncology in a clinical and/or laboratory setting in the United States or Canada. Over thirty neuro-oncology facilities agreed to be listed as a potential host for the SNO International Outreach Research Fellow (a full list is available on the SNO website). The fellowship is open to post-graduate medical professionals working in the following areas: neurosurgery, neurology, radiation oncology, medical oncology, pathology, radiology, neuropathology, allied health or basic science. The applicant must be living outside of North America when the application is submitted and must not be a citizen of the United States or Canada, and preference will be given to applicants from developing regions. Also considered will be the potential impact to the advancement of neuro-oncology in the applicant’s home country upon completion of the fellowship. Thanks to the support of ABTA and EMD Serono, SNO will be able to make one $50,000 fellowship award in 2010, 2011 and 2012.

**Travel Scholarships**

Building on the positive response we had to the travel scholarship program initiated for our 2008 annual meeting in Las Vegas, the International Outreach Committee has decided to again provide travel funds for our 2010 meeting which will take place in Montreal, Canada. Travel scholarships in the amount of $1,500 each will be awarded to applicants in each of the following underserved geographical areas: Central America & the Caribbean, Central and Southern Africa, China & associated countries, Eastern Europe, Far East & Australasia, Indian Sub-Continent, North Africa & the Middle East and South America. To qualify for an award the applicant must be living and working outside the United States or Canada, have a professional focus in neuro-oncology, and be otherwise unable to attend the SNO meeting and foster neuro-oncology education with their colleagues upon their return to their home country.

**Other Outreach Activities**

Another important element of our international outreach efforts has been to extend the availability of our journal, Neuro-Oncology, through discounted subscriptions to individuals, academic centers and hospitals in countries of low per capita GNP. With the Society’s new partnership with Oxford University Press, we anticipate building on this commitment through Oxford’s already well-established distribution channels that provide free and greatly reduced fees for online access to many of their journals in low income countries. SNO will also be participating in other initiatives including the International Network for the Availability of Scientific Publications (INASP), which collaborates with publishers in the developed world to facilitate access to research within developing countries, and the Health InterNetwork Access to Research Initiative (HINARI) which is led by the World Health Organization (WHO) and supports medical professionals in 113 countries by providing access to over 3,750 biomedical and health journals.

Finally, this year we are pleased to welcome Eric Bouffet as the new vice-chair of the International Outreach Committee. Dr. Bouffet has wealth of international experience and we look forward to working with him on this important SNO initiative.

**Redeveloped Website**

The internet plays an ever-increasing role in the way non-profit associations communicate with their members, and this year the Society decided to embark on a complete redevelopment of its website. Far from merely adding new graphics and images, the new SNO website represents a fundamental change in the way SNO members interact with the administrative office. For example, SNO members had been required to use third-party sites for various functions, including membership renewal and meeting registration. In the future, our members will enjoy the convenience of being able to complete these essential e-commerce transactions directly, and securely, on the SNO website. In addition, the new site will feature an improved calendar of upcoming events, an enhanced “members area” and more timely news and feature articles. The Society thanks Erik Sulman, co-chair of the SNO communications committee, for his work on the redevelopment of the SNO site.

**Boutique Meetings**

In addition to our marquee annual event, the SNO Scientific Meeting and Education Day, the SNO administrative office is also active in organizing smaller, specialized meetings that reflect the diverse educational needs of our multidisciplinary membership. The Neuro-Tumor Dinner Meeting, held each year in conjunction with the AACR Annual Meeting, provides attendees with an informal and stimulating exchange of late-breaking findings of specific and focused interest to investigators dedicated to brain tumor research. Our 2009 Dinner, organized by Nicholas Foreman and Michael Handler, was held in Denver and attracted over 170 researchers—a record level of attendance. In the future, SNO will be also exploring other boutique type meetings, including an event focusing on basic and translational pediatric research.

**Effective Platforms for Communication and Exchange**

With the increasing volume and complexity of neuro-oncology research resulting from advances in basic and translational science, the Society for Neuro-Oncology must ensure that we provide our members with effective platforms for communication and exchange. Although the Society is not directly involved in the conduct of clinical research, SNO is uniquely positioned to ensure the timely translation of results to the clinical setting. Whether it be in the form of educational meetings, the expansion of our journal to monthly publication or our web-based resources, SNO strives to create effective methods to facilitate communication among our interdisciplinary members.
The following preliminary financial highlights are presented by the management of the Society for Neuro-Oncology as of June 30, 2008:

<table>
<thead>
<tr>
<th>Account</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$276,000</td>
</tr>
<tr>
<td>Investments</td>
<td>936,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>12,000</td>
</tr>
<tr>
<td>Endowment Assets</td>
<td>187,000</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$1,411,000</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>55,000</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td>1,212,000</td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td>$1,267,000</td>
</tr>
</tbody>
</table>

The following preliminary financial highlights are presented by the management of the Society for Neuro-Oncology for the fiscal year ended June 30, 2008:

<table>
<thead>
<tr>
<th>Account</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$1,155,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses¹</td>
<td>908,000</td>
</tr>
<tr>
<td><strong>Net Income/(Loss) from Operations</strong></td>
<td>$247,000</td>
</tr>
</tbody>
</table>

¹Excludes one-time charge resulting from change in publishing partner.

The following preliminary financial highlights are presented by the management of the Society for Neuro-Oncology as of June 30, 2009:

<table>
<thead>
<tr>
<th>Account</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$374,000</td>
</tr>
<tr>
<td>Investments</td>
<td>582,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>12,000</td>
</tr>
<tr>
<td>Endowment Assets</td>
<td>105,000</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$1,073,000</td>
</tr>
<tr>
<td><strong>Total Liabilities</strong></td>
<td>20,000</td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
<td>1,394,000</td>
</tr>
<tr>
<td><strong>Total Liabilities and Net Assets</strong></td>
<td>$1,414,000</td>
</tr>
</tbody>
</table>

The following preliminary financial highlights are presented by management of the Society for Neuro-Oncology for the fiscal year ended June 30, 2009:

<table>
<thead>
<tr>
<th>Account</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$1,259,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>1,089,000</td>
</tr>
<tr>
<td><strong>Net Income from Operations</strong></td>
<td>$170,000</td>
</tr>
</tbody>
</table>
Awards Committee
The Awards Committee is charged with developing criteria for SNO awards, annually reviewing award candidates, and forwarding to the Board a list of Awards and award recipients to be honored at the Annual Meeting.
Chair: Kenneth Aldape, MD

Audit Committee
The Audit Committee is a newly formed committee and is composed of a Chair and Vice Chair, the Vice President, the Secretary-Treasurer, the Executive Director, and additional designated members as necessary. The committee has the responsibility of overseeing annual internal audits of Society financial affairs, and conveying an annual report to the President and the Board, who may approve review of the audit by external committees as needed. The committee also advises and makes recommendations to the Board of Directors based on the findings of such audits.
Chair: Gene Barnett, MD

Bylaws Committee
The Bylaws Committee reviews the Bylaws at least annually (more frequently as issues arise) and makes recommendations for revision as necessary. Members of this committee shall also review any proposed changes and advise the Board of Directors on proposed revisions.
Chair: Kurt A. Jaeckle, MD
Vice Chair: Ian McCutcheon, MD

Communications Committee
The Communications Committee is composed of a Chair and Vice Chair, the Executive Director and Chief Administrative Officer, the Secretary-Treasurer, and Chairs of the Awards and Education Committees. This committee has the responsibility of advising and making recommendations to the Board of Directors on issues pertaining to the publications of the Society.
Co-Chair: Erik Sulman, MD, PhD
Co-Chair: Christopher Pellekisi, MD
Education Committee
The Education Committee advises the Board of Directors on all projects concerning education in the field of neuro-oncology, including planning of the Education Day.
Chair: Patrick Wen, MD

Future Sites Committee
The Future Sites Committee reviews potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue.
Chair: Walter A. Hall, MD
Vice Chair: Lynn Ashby, MD

International Outreach Committee
The International Outreach Committee is another newly formed committee. It is composed of a Chair and Vice-Chair, the President and Vice President of the Society, and other representative International members recommended by the Chair or President, as approved by the Board of Directors. The committee will have the responsibility of advising and making recommendations to the Board of Directors on all projects concerning education and other significant matters related to the field of neuro-oncology nursing. This committee also coordinates educational activities for the nursing membership, including workshops, satellite symposia or special sessions involving neuro-oncology nursing. The committee will coordinate the program for these educational activities in conjunction with the Education and Scientific Program Committees, and such programs will primarily be conducted at the Annual Society or World Federation Meetings.
Chair: Nooren Lahey, MS
Vice Chair: Vanessa Nestor, MS

Nursing Committee
The Neuro-oncology Nursing Committee is a third new committee. It is composed of a Chair and Vice Chair, and other members who will have the responsibility of advising and making recommendations to the Board of Directors on all projects concerning education and other significant matters related to the field of neuro-oncology nursing. This committee also coordinates educational activities for the nursing membership, including workshops, satellite symposia or special sessions involving neuro-oncology nursing. The committee will coordinate the program for these educational activities in conjunction with the Education and Scientific Program Committees, and such programs will primarily be conducted at the Annual Society or World Federation Meetings.
Chair: Jonathan Finlay, MD
Vice Chair: Eric Bouffet, MD

Membership Committee
The Membership Committee is charged with reviewing and voting on all applicants for membership. Responsibilities include the evaluation of a member’s professional conduct as requested by a majority of the Board of Directors, and development of initiatives to promote membership.
Chair: Larry Kun, MD
Vice Chair: Arnab Ghakravarti, MD

Platinum Level
American Brain Tumor Association
EMD Serono
Genentech
National Brain Tumor Society
Pediatric Brain Tumor Foundation
Schering Plough Oncology
Sontag Foundation

Gold Level
AstraZeneca
Bristol-Myers Squibb
CERN Foundation
Essai

Silver Level
Eli Lilly

Bronze Level
Braedner Pharmaceuticals
Northwest Biotherapeutics
Tug McGraw Foundation

President’s Club
Dean
Jeffrey S. Brindile, MD
Stanislav R. Burzynski, MD, PhD
Morris D. Groves, MD, JD
Abhijit Guha, MD
Kevin Murray, MD
Raymond E. Sawaya, MD
Edward G. Shaw, MD
Childhood Brain Tumor Foundation

Professor
Jonathan L. Finlay, MD
Gregory N. Fuller, MD, PhD
John G. Golfinos, MD
Walter A. Hall, MD
Minesh Mehta, MD
Stephen K. Powers, MD
James T. Ruika, MD
Christopher Schultz, MD
Mark E. Shaffrey, MD
Erwin Van Meir, PhD

Associate
Oliver Bogler, PhD
Michael R. Chicoine, MD
Ali K. Ghousair, MD
Charles Heddorfer, MD
Carol Kruchko
Christina A. Meyers, PhD
Elizabeth W. Newcomb, MD
Michael A. Vogelbaum, MD, PhD

Fellow
Jeffrey Allen, MD
Henry Brem, MD
Michael Custodino, MD
Waldemar Debinski, PhD
Bonnie Feldman
Karen L. Fink, MD, PhD
Alexandra Flowers, MD
Peter A. Forsyth, MD, FRCP
Henry S. Friedman, MD
Jeffrey Goldman, MD
Robert Jenkins, MD, PhD
Arie Perry, MD
Surask Phuphanich, MD
Jeffrey Raizer, MD
Gerald Rosen, MD
Adrienne C. Schect, PhD
Jeffrey W. Sherman, MD
Robert L. Tufel

Victor Levin Founders Society
Mr. and Mrs. Robert Flesham
Brian L. Greenspun
Victor A. Levin, MD
Harold and Pamela Ruttenberg
Schering-Plough Corporation
W. K. Alfred Yung, MD

SNO Partners

Cheryl Alger Memorial Donations
Sean Alger
Roland Benjamin
Johanna T. Bryant
James and Julie Corrigan
Kathy E. Hart
Laurie Kelley
Richard and Lorraine Kerins
Carol Komosa
Gregory and Karen Longendyke
Edward and Donna Marsh
Brian and Annette Murphy
Patti Anne Murphy
Jim and Susan E. Stepp
Johanna Travis
Carol-Lee Wojciehowski
Gateway Community Industries on behalf of Victoria Gore

Neuro-Tumor Club Meeting
American Brain Tumor Association
Castle Biosciences
Morgan Adams Foundation
EMD Serono
National Brain Tumor Society
Pediatric Brain Tumor Foundation
Schering-Plough Corporation

Morgan Adams Foundation
American Brain Tumor Association
Castle Biosciences
Morgan Adams Foundation
EMD Serono
National Brain Tumor Society
Pediatric Brain Tumor Foundation
Schering-Plough Corporation

SNO Partners gratefully acknowledges the pro bono accounting services provided by William M. Shields, PC, since 1996.

SNO Partners

SNO Partners

SNO Partners
Mission
SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

Vision
SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.

SNO Members

- Neuro-oncology: 18%
- Neurosurgery: 19%
- Radiation Oncology: 10%
- Medical Oncology: 8%
- Basic Science: 16%
- Pediatric Oncology: 7%
- Pathology: 5%
- Associate: 10%
- Other: 7%
- Medical Oncology: 8%
- Radiation Oncology: 1%
- Psychology: 1%
- Pharmacology: 1%
- Epidemiology: 1%
- Statistics: 1%
- Nursing: 2%
- Associate: 10%